Geriatric oncology: European Union regulatory perspectives and initiatives.
The world population is gradually ageing. With cancer being prominently a disease of the elderly, availability of information for oncology drugs in this patient population is becoming critical for their safe and effective use. Drug regulatory thinking and recommendations towards obtaining this information continue to evolve over time accordingly in order to address this information gap.
European Medicines Agency, 7 Westferry Circus, London E14 4HB, UK. Electronic address: Iordanis.Gravanis@ema.europa.eu.
Iordanis
I
Gravanis
D000368:Aged; D000970:Antineoplastic Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D017277:Drug Approval / Q000331:legislation & jurisprudence; D023381:Endpoint Determination; D005062:European Union; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000453:epidemiology; D061214:Patient Safety; D011157:Population Dynamics
D000970:Antineoplastic Agents